Results 81 to 90 of about 3,260 (145)

A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia

Oncology and Therapy
The approval of ibrutinib over a decade ago introduced Bruton tyrosine kinase (BTK) inhibition as a foundational, chemotherapy-free treatment approach for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Paolo Ghia, Jennifer R. Brown, Mazyar Shadman, Clemens-Martin Wendtner   +3 more
doaj   +1 more source

Zanubrutinib for Immunoglobulin A Vasculitis With Monoclonal Gammopathy

This case report describes a patient in his 50s with immunoglobulin A vasculitis with monoclonal B-cell lymphocytosis who was successfully treated with zanubrutinib after failure of multiple treatments.
Alencar, Alvaro J, Cohen, Jonathan J, Maderal, Andrea D, Warp, Peyton V, Desai, Karishma R   +4 more
core   +1 more source

Highly Enantioselective Ir-Catalyzed Hydrogenation of Pyrazolo[1,5‑a]pyrimidine for the Synthesis of Zanubrutinib

A highly enantioselective catalytic reduction of pyrazolo[1,5-a]pyrimidine to zanubrutinib has been realized by the Ir/(R)-t-Bu-FcPhox complex. This chiral product could be obtained in up to >99% ee in the asymmetric transformation without any other ...
Xian Liu (191882), Wei Yao (30303), Yuanyuan Hao (402713), Haohuan Yuan (17835862), Ru Jiang (587001), Zhao Wei (3095598), Xiaomin Zhang (136250), Jiayue Xi (17835865), Huifang Nie (1816438)   +8 more
core   +1 more source

Extranodal Lymphoplasmacytic Lymphoma Responding Rapidly to Zanubrutinib: A Case Series [PDF]

Management of recurrent or atypical lymphoplasmacytic lymphoma poses a significant therapeutic challenge. Here we demonstrate a case series of three patients with atypical presentations of extranodal lymphoplasmacytic lymphoma that each show remarkable ...

core   +3 more sources

Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study

Clinical and Translational Medicine
Background CD19 chimeric antigen receptor (CAR) T‐cell therapy is a potential treatment for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL).
Rong Shen, Wei‐Guo Cao, Li Wang, Ling‐Shuang Sheng, Yi‐Lun Zhang, Wen Wu, Peng‐Peng Xu, Shu Cheng, Meng‐Ke Liu, Yan Dong, Yue Wang, Xiang‐Qin Weng, Xu‐Feng Jiang, Qi Song, Hong‐Mei Yi, Lei Li, Sheng Chen, Zi‐Xun Yan, Wei‐Li Zhao   +18 more
doaj   +1 more source

Zanubrutinib-Induced Acneiform Rash in a Patient With Waldenstrom’s Macroglobulinemia

Case Reports in Medicine
Waldenström’s macroglobulinemia is a rare lymphoproliferative disorder that can be treated with Bruton’s Tyrosine Kinase inhibitors (BTKi), including zanubrutinib.
Silvia Robuffo, Corrado Zengarini, Claudio Agostinelli, Elena Sabattini, Michelangelo La Placa, Bianca Maria Piraccini, Alessandro Pileri   +6 more
doaj   +1 more source

Real-world effectiveness and safety of Zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma.

There is no established standard treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL). Zanubrutinib was approved in this setting based on the phase II MAGNOLIA trial.
Jimena Cannata-Ortiz, Ana Jiménez-Ubieto, Pablo Galindo-Navarro, Itxaso Amarika, Sofía Martín-Consuegra, Sergio Ramos Cillan, Juan Gonzalo Correa, Nazaret Domínguez, Maria José Otero, Ana Muntanola Prat, Mariana Bastos-Oreiro, Norma C. Gutierrez, Lucia Villalon, Ramón Diez-Feijóo, Joan-Alfons Soler, Cristina García-Herce, Carolina Villegas, Dunia de Miguel Llorente, Antonio Salar, Lucía Morais, Xabier Gutierrez Lopez De Ocariz, Miriam Moreno, Aranzazu Alonso, Alessandra Comai, Ángeles Medina, Paola Villafuerte Gutierrez, Fernando Martin-Moro, Maria Luisa Bengochea Casado, Javier López-Marín, Javier Marco Ayala, Armando López-Guillermo, Esperanza Lavilla Rubira, Sara Fernández-Luis, Rafael Lluch García, Beatriz de la Cruz Benito, Horacio Gulino, José-María Arguiñano, Eva Domingo-Domenech, Marta Aceituno, Maria Sofia Vazquez Diaz   +39 more
core   +1 more source

Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia

Journal of Comparative Effectiveness Research
Aim: To estimate cost savings associated with covalent Bruton’s tyrosine kinase inhibitor (cBTKi) choice in patients with treatment-naive (TN) and relapsed/refractory (RR) chronic lymphocytic leukemia (CLL) from a Medicare perspective.
Adam S Kittai, Dipen A Patel, Jason Shafrin, Nadine Zawadzki, Vikram S Shetty, Yazan K Barqawi, Joanna M Rhodes   +6 more
doaj   +1 more source

Clinical improvement of pemphigus-like mucocutaneous disease in a patient with CLL following initiation of zanubrutinib: a case report. [PDF]

Front Immunol
Li T, Lu C, Kang T, Tu Y, Sun D.
europepmc   +1 more source

Peripheral and central nervous system toxicities of Bruton tyrosine kinase Inhibitors: a real-world pharmacovigilance study. [PDF]

Front Med (Lausanne)
Zhang J.
europepmc   +1 more source